Aggregation Limiting Cell-Penetrating Peptides Derived from Protein Signal Sequences

Area of Science:

• Neurodegenerative diseases
• Biochemistry
• Molecular biology

Background:

• Alzheimer's disease (AD) is a leading cause of dementia, characterized by amyloid-beta (Aβ) plaques and neurofibrillary tangles.
• Current treatments for AD are limited, highlighting the need for novel therapeutic strategies targeting disease mechanisms.
• Understanding the heterogeneous pathophysiology of AD is crucial for developing effective interventions.

Purpose of the Study:

• To investigate novel peptide sequences for their ability to reduce amyloid-beta (Aβ) aggregation in vitro.
• To explore the potential of modified signal peptides, including those derived from transthyretin, as therapeutic agents for Alzheimer's disease.
• To assess the cell-penetrating and anti-inflammatory properties of these novel peptides.

Main Methods:

• In vitro assessment of amyloid-beta (Aβ) aggregation using modified signal peptides, including transthyretin-derived sequences.
• Evaluation of cell-penetrating peptide (CPP) properties of modified peptides in mammalian cells.
• Utilizing an Aβ-EGFP fusion protein to efficiently monitor aggregation reduction and CPP efficacy.

Main Results:

• Transthyretin-derived peptides, similar to NCAM1 signal sequences, effectively reduce amyloid-beta (Aβ) aggregation in vitro.
• Modified signal peptides demonstrated cell-penetrating properties and are predicted to possess anti-inflammatory effects.
• The Aβ-EGFP fusion protein system proved effective for assessing peptide-mediated aggregation reduction and CPP activity.

Conclusions:

• Novel modified signal peptides, particularly those derived from transthyretin, represent a promising therapeutic avenue for reducing amyloid-beta (Aβ) aggregation in Alzheimer's disease (AD).
• These peptides offer potential dual benefits of targeting Aβ aggregation and exhibiting anti-inflammatory properties.
• The developed Aβ-EGFP fusion protein assay provides a robust platform for future screening of AD-targeting peptides.